Adrenal gland: Adrenocortical carcinoma—first RCT

Abstract

Results have been published for the FIRM-ACT trial of etoposide, doxorubicin, cisplatin and mitotane (EDP-M) versus streptozocin and mitotane in advanced adrenocortical carcinoma. “The main finding is clear,” says Martin Fassnacht, the study’s corresponding author. “EDP-M is superior to streptozocin plus mitotane and thus should be considered the standard firstline [cytotoxic] treatment in all patients with adrenocortical carcinoma.” The rarity of adrenocortical carcinoma (annual incidence rate 0.7–2.0 cases per million individuals) has greatly hampered previous research in this field. “Most participants in [the first international symposium on adrenocortical carcinoma, held in 2003] judged it unrealistic to organize an international trial with more than 300 patients,” notes Fassnacht. “However, Britt Skogseid, Massimo Terzolo and myself accepted this challenge, and finally with the support of many, many investigators (mainly in Europe, but also in the USA, Canada and Australia) we finally succeeded.” The study was eventually conducted in ADRENAL GLAND

DOI: 10.1038/nrendo.2012.79

Cite this paper

@article{Barranco2012AdrenalGA, title={Adrenal gland: Adrenocortical carcinoma—first RCT}, author={Caroline Barranco}, journal={Nature Reviews Endocrinology}, year={2012}, volume={8}, pages={384-384} }